Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer patients: is efficacy maintained?

Monoclonal antibodies bevacizumab and cetuximab both improve overall survival (OS), progression free survival (PFS) and overall response rate (ORR) when combined with irinotecan-containing regimens. The optimal sequence of these monoclonal antibodies in combination with chemotherapy is controversial...

Descripción completa

Detalles Bibliográficos
Autores principales: Grande, Roberta, Gemma, Donatello, Sperduti, Isabella, Gelibter, Alain, Giampaolo, Maria Anna, Trombetta, Giorgio, Nelli, Fabrizio, Gamucci, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing AG 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647091/
https://www.ncbi.nlm.nih.gov/pubmed/23667824
http://dx.doi.org/10.1186/2193-1801-2-185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647091/
https://www.ncbi.nlm.nih.gov/pubmed/23667824
http://dx.doi.org/10.1186/2193-1801-2-185

Ejemplares similares